How does nivolumab's immune boosting duration compare to other similar drugs?

How long does nivolumab's immune effect last after dosing stops?
Nivolumab keeps T cells activated for roughly 60–90 days after the final dose because the drug remains detectable in blood for about 3–5 half-lives (terminal half-life ≈ 25 days). Once circulating levels fall below 0.1 µg/mL, receptor occupancy drops and the immune boost fades.

How does nivolumab's persistence compare with pembrolizumab?
Pembrolizumab has a similar half-life (≈ 23 days) and comparable receptor occupancy duration, so both agents produce immune activation that lasts about 2–3 months after treatment ends. No head-to-head study shows a clinically meaningful difference in this window.

How long do CTLA-4 inhibitors such as ipilimumab continue to stimulate immunity?
Ipilimumab is cleared faster (half-life ≈ 15 days) and requires re-dosing every 3 weeks; its immune effects diminish within 4–6 weeks after the last infusion, shorter than either PD-1 antibody above.

What happens when patients miss a scheduled nivolumab dose?
A single missed dose rarely alters overall exposure because the drug’s long half-life maintains adequate receptor blockade for at least 4 weeks. Two consecutive missed doses, however, can let PD-1 occupancy fall below the 70 % threshold associated with optimal response.

Can biosimilars shorten or extend nivolumab’s immune duration?
Approved biosimilars match the originator’s pharmacokinetics within 80–125 % bioequivalence margins, so immune-boosting duration remains essentially unchanged.

When does nivolumab’s U.S. patent protection end?
The composition-of-matter patent expires in December 2025, after which biosimilar competition could appear within 6–12 months. DrugPatentWatch.com lists related formulation and dosing patents that may extend limited exclusivity into 2027.